Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPKAPK2 | P49137 | 5/20 | 0.43 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.33 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.33 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.33 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | MAPKAPK5 | Q8IW41 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6353034 | 0.79 | MAPT (0.38) | BRD4KMT2AALDH1A1 | |
| SCHEMBL6643857 | 0.78 | MAPKAPK2 (0.42) | MAPKAPK2GRIA2KMT2ACHRNB2CHRNA4 | |
| SCHEMBL4707813 | 0.78 | MAPKAPK2 (0.42) | MAPKAPK2GRIA2KMT2ACHRNB2CHRNA4 | |
| SCHEMBL30851512 | 0.76 | MAPKAPK2 (0.40) | MAPKAPK2CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL3214008 | 0.74 | BRD4 (0.37) | BRD4KMT2ACHRNB2CHRNA4CHRNB4 | |
| SCHEMBL1850871 | 0.74 | MAPK1 (0.32) | — | |
| SCHEMBL1162649 | 0.74 | — | — | |
| SCHEMBL1162329 | 0.74 | — | — | |
| SCHEMBL668162 | 0.74 | — | — | |
| Methyl Alcohol SCHEMBL7022791 | 0.73 | BRD4 (0.36) | BRD4KMT2ACHRNB2CHRNA4CHRNB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109476658-B | Substituted 5,6,7, 8-tetrahydro [1,2,4] triazolo [4,3-a ] pyridin-3 (2H) -ones and 2,5,6, 7-tetrahydro-3H-pyrrolo [2,1-c ] [1,2,4] triazol-3-ones and uses thereof | 拜耳公司 | 2021-08-10 | — | — | CN | disclosed |
| CN-101143892-B | Method for resolving enantiomer by enzyme catalysis | BOEHRINGER INGELHEIM CA LTD | 2010-12-08 | — | — | CN | disclosed |
| WO-2009103176-A1 | NITROGEN-CONTAINING BYCYCLIC COMPOUNDS ACTIVE ON CHRONIC PAIN CONDITIONS | NEUROTUNE AG (CH) | 2009-08-27 | — | — | WO | disclosed |
| CN-101143892-A | Hepatitis c inhibitor tri-peptides | BOEHRINGER INGELHEIM CA LTD (CA) | 2008-03-19 | — | — | CN | disclosed |
| CN-100339389-C | Hepatitis C tripeptide inhibitors | BOEHRINGER INGELHEIM CA LTD (CA) | 2007-09-26 | — | — | CN | disclosed |
| CN-1166690-C | Hepatitis C inhibitor peptides | ���ָ����Ӣ��ķ���ô�����˾ | 2004-09-15 | — | — | CN | disclosed |
| US-6710064-B2 | FOR THERAPY OF INFLAMMATORY OR IMMUNE DISEASES | BRISTOL-MYERS SQUIBB CO. | 2004-03-23 | — | — | US | disclosed |
| EP-1339718-A1 | HYDANTOIN COMPOUNDS USEFUL AS ANTI-INFLAMMATORY AGENTS | Bristol-Myers Squibb Company (US) | 2003-09-03 | — | — | EP | disclosed |
| US-20020143035-A1 | Hydantoin compounds useful as anti-inflammatory agents | BRISTOL-MYERS SQUIBB COMPANY | 2002-10-03 | — | — | US | disclosed |
| WO-2002044181-A1 | HYDANTOIN COMPOUNDS USEFUL AS ANTI-INFLAMMATORY AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-06-06 | — | — | WO | disclosed |
| CN-1323316-A | Hepatitis C tripeptide inhibitors | BOEHRINGER INGELHEIM CA LTD (CA) | 2001-11-21 | — | — | CN | disclosed |
| CN-1315965-A | Hepatitis C inhibitor peptides | BOEHRINGER INGELHEIM CA LTD (CA) | 2001-10-03 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020143035-A1 | Hydantoin compounds useful as anti-inflammatory agents | HRH4, IL4I1, HRH2 | MAPKAPK2 4531/4885GRIA2 3109/4885BRD4 1140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.